New Data from HELIOS-B Phase 3 Study Presented at the Heart Failure Society Annual Scientific Meeting

28 Sep, 2025 New Data from HELIOS-B Phase 3 Study Presented at the Heart Failure Society Annual Scientific Meeting

Late-breaking abstract from the HELIOS-B Phase 3 study showed vutrisiran significantly lowered rates of gastrointestinal events, a common disease manifestation of ATTR-CM, by up to 49% in patients.

Additional HELIOS-B analyses validate the efficacy and safety of vutrisiran as a monotherapy in ATTR-CM and support the consistent benefit of vutrisiran treatment in ATTR-CM patients regardless of baseline health status and quality of life.

Urey, et al. “Evidence of Fewer Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran Compared with Placebo: Analysis from HELIOS-B”

Witteles, et al. “Outcomes of the HELIOS-B Monotherapy Population: A Post Hoc Analysis Censoring Data Following Tafamidis Initiation”

Huttin, et al. “Efficacy of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy by Baseline Health Status and Quality of Life”